Showing 591-600 of 9402 results for "".
Otezla Approved for Plaque Psoriasis
https://practicaldermatology.com/topics/psoriasis/dermiretv-otezla-approved-for-plaque-psoriasis/19031/In this week's edition of DermWireTV from the publishers of Practical Dermatology® magazine and DermWire.com, a look at Celgene's Otezla for psoriasis--the first PDE4 inhibitor approved for plaque psoriasis. Plus, Ranbaxy's new dosage strengths of Absorica (isotretinoin), and Galderma's search for pUpdate on Topical Acne Therapy for Adult Women
https://practicaldermatology.com/topics/general-topics/update-on-topical-acne-therapy-for-adult-women/19166/Diane Berson, MD, FAAD discusses the approach to management of acne in the adult female patient, emphasizing the role of vehicle to affect the patient experience, promote adherence, and optimize outcomes. Bonus Material: Hormonal Therapy for Female Acne Bonus Material: Procedures for Adult Female APromising Therapies on the Atopic Dermatitis Horizon
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37178/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, previews important potential developments in the atopic dermatitis pipelineMechanisms of Action for IL-17 Inhibition in Treating Psoriasis and Hidradenitis Suppurativa
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/mechanisms-of-action-for-il-17-inhibition-in-treating-psoriasis-and-hidradenitis-suppurativa/48808/Practical Dermatology Editorial Board member Jason E. Hawkes, MD, MS, FAAD, joins Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss articles from the Journal of Clinical Medicine and Clinics in Dermatology on how IL-17 inhibition is effective in treating psoriasis and hidradenitis suppurativa,Practical Dermatology Roundtable: The Role of Adjuvant Skin Cleansing and Moisturizing in Treating Psoriasis and Other Inflammatory Diseases, Ch. 7
https://practicaldermatology.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-the-role-of-adjuvant-skin-cleansing-and-moisturizing-in-treating-psoriasis-and-other-inflammatory-diseases-ch-7/56875/In the seventh installment of this eight-part series, host Ted Lain, MD, MBA, FAAD, and guests Zoe Diana Draelos, MD, and Firas George Hougeir, MD, FAAD, shift to clinical applications, including maintenance therapy, steroid-sparing strategies, and opportunities for future research.1 Draelos Z, HouSequencing Therapies for Long-Term Control of Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/sequencing-therapies-for-long-term-control-of-atopic-dermatitis/48786/Christopher Bunick, MD, FAAD, talks about the six effective and safe advanced systemic therapies for atopic dermatitis and how to prescribe them for patients as early as possible by understanding the guidelines and the labels.Origins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).Step Therapy Reform Advocates Seek to Spread Awareness of Proposed Law
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/step-therapy-reform-advocates-seek-to-spread-awareness-of-proposed-law/33160/The Safe Step Act would stop insurance companies under certain circumstances from requiring alternative medications before covering biologics.What's New in Atopic Dermatitis?
https://practicaldermatology.com/programs/practical-dermatology/whats-new-in-atopic-dermatitis/33014/Emma Guttman, MD, PhD, professor and chair of dermatology at Mount Sinai, talks about the latest developments in treatments and therapies for atopic dermatitis.Analysis Evaluates Risks of Cardiovascular Events Among Biologics for Psoriatic Diseases
https://practicaldermatology.com/series/dermwire-tv/analysis-evaluates-risks-of-cardiovascular-events-among-biologics-for-psoriatic-diseases/32412/In this week's DermwireTV, a new analysis evaluates the risks of major adverse cardiovascular events among patients treated with biologics for psoriatic diseases; a phase 3 clinical trial examines the use of nemolizumab in adults with prurigo nodularis; and the president of Journey Medical discusses